(Q33404332)

English

Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Satoshi Igawa

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Shinichiro Ryuge

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Mayuko Wada

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sakiko Otani

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sachiyo Maki

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Akira Takakura

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ken Katono

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jiichiro Sasaki

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yuichi Sato

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Noriyuki Masuda

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

7 November 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

58

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

313-320

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.

1 reference

https://api.crossref.org/works/10.1159%2F000343048

21 January 2018

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1159%2F000343048

21 January 2018

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1159%2F000343048

21 January 2018

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1159%2F000343048

21 January 2018

Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent

1 reference

https://api.crossref.org/works/10.1159%2F000343048

21 January 2018

The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action

1 reference

https://api.crossref.org/works/10.1159%2F000343048

21 January 2018

Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1159%2F000343048

21 January 2018

The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1159%2F000343048

21 January 2018

Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1159%2F000343048

21 January 2018

Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.

1 reference

https://api.crossref.org/works/10.1159%2F000343048

21 January 2018

Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1159%2F000343048

21 January 2018

Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials

1 reference

https://api.crossref.org/works/10.1159%2F000343048

21 January 2018

Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study

1 reference

https://api.crossref.org/works/10.1159%2F000343048

21 January 2018

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

1 reference

https://api.crossref.org/works/10.1159%2F000343048

21 January 2018

Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1159%2F000343048

21 January 2018

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1159%2F000343048

21 January 2018

A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in China

1 reference

https://api.crossref.org/works/10.1159%2F000343048

21 January 2018

Low-dose weekly docetaxel is as tolerable as pemetrexed in previously treated advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1159%2F000343048

21 January 2018

A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1159%2F000343048

21 January 2018

Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung

1 reference

https://api.crossref.org/works/10.1159%2F000343048

21 January 2018

Identifiers

10.1159/000343048

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33404332&oldid=1536375834"